Safety and Immunogenicity of Human Papillomavirus Quadrivalent Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System
Latest Information Update: 28 May 2024
Price :
$35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary) ; Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors PharmaJet
- 22 May 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 21 Mar 2024 Planned End Date changed from 30 Dec 2024 to 30 Apr 2025.
- 21 Mar 2024 Planned primary completion date changed from 30 Aug 2024 to 30 Dec 2024.